Currently, an Investigator Global Assessment (IGA) for drug registration in atopic dermatitis (AD) lacks standardization. Establishing of a validated IGA scale along with a training module would enhance the assessment of disease severity in AD clinical trials.
Learn more at the Journal of the American Academy of Dermatology.